NCT07516132Phase 3Recruiting

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Study sponsor: Ocular Therapeutix, Inc. · OCUL

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2030-08-01Estimated

Enrollment · participants850Estimated

Source updated2026-07-01Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-01 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Neovascular Age-Related Macular Degeneration (nAMD)

Treatments or interventions studied

OTX-TKIDrug

Primary outcomes · main study measures

Read the study measures

measure: Incidence and severity of treatment-emergent adverse events (TEAEs) from Baseline (Day 1) through Week 144; description: Number of events; timeFrame: from Baseline (Day 1) through Week 144; measure: Proportion of participants with severe vision loss (defined as ≥ 30 Early Treatment Diabetic Retinopathy Study [ETDRS] letters loss) from Baseline (Day 1) through Week 144; description: Percentage; timeFrame: from Baseline (Day 1) through Week 144

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history